APA (7th ed.) Citation

A, N., A, B., C, B., H, S., A, H., D, C., . . . V, M. (2020). Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. Journal of medicinal chemistry, 63(19), 10773. https://doi.org/10.1021/acs.jmedchem.0c00499

Chicago Style (17th ed.) Citation

A, Nagle, et al. "Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases." Journal of Medicinal Chemistry 63, no. 19 (2020): 10773. https://doi.org/10.1021/acs.jmedchem.0c00499.

MLA (9th ed.) Citation

A, Nagle, et al. "Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases." Journal of Medicinal Chemistry, vol. 63, no. 19, 2020, p. 10773, https://doi.org/10.1021/acs.jmedchem.0c00499.